This week, scientists use tears to draft a proteomic signature for glaucoma diagnosis, Acucela’s treatment for Stargardt disease receives orphan designation in Europe and early findings suggest gold contact lenses may protect eyes from damaging light. Source: AAO
This study assessed immediate versus delayed prescription of glasses for managing moderate hyperopia in young children. Source: AAO
This study evaluated how retinal artery occlusions caused by cosmetic facial filler injections affect retrobulbar blood flow parameters. Source: AAO
This study describes a novel device and technique for Epi-Bowman blunt keratectomy (EBK) that is designed to minimize pain and accelerate re-epithelialization compared with the use of diluted ethanol in myopic photorefractive keratectomy (PRK). Source: AAO
Findings from a pair of phase 3 trials suggest that the new VEGF inhibitor brolucizumab is more effective than aflibercept at resolving retinal fluid in patients with wet AMD. Source: AAO
The FDA granted orphan drug designation to a synthetic peptide for treatment of noninfectious intermediate, posterior, chronic anterior and panuveitis. Source: AAO
This week, children retain visual perception after surgery to remove the visual cortex, a Florida clinic is forced to halt unapproved stem cell treatments and risuteganib shines in a phase 2 trial for dry AMD. Source: AAO
In this study, researchers identified factors contributing to the misdiagnosis of optic nerve sheath meningiomas (ONSM). Source: AAO
This study assessed the long-term incidence and prevalence of uveitis and its association with multiple sclerosis. Source: AAO
This study examined the importance of nuclear factor kappa-beta (NFKB) in patients with rosacea. Source: AAO